Faricimab Treat-and-Extend for Diabetic Macular Edema
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
PURPOSE: To evaluate the 2-year efficacy, durability, and safety of dual angiopoietin-2 and vascular endothelial growth factor (VEGF) A pathway inhibition with intravitreal faricimab according to a personalized treat-and-extend (T&E)-based regimen with up to every-16-week dosing in the YOSEMITE and RHINE (ClinicalTrials.gov identifiers, NCT03622580 and NCT03622593, respectively) phase 3 trials of diabetic macular edema (DME). DESIGN: Randomized, double-masked, noninferiority phase 3 trials. PARTICIPANTS: Adults with visual acuity loss (best-corrected visual acuity [BCVA] of 25-73 letters) due to center-involving DME. METHODS: Patients were randomized 1:1:1 to faricimab 6.0 mg every 8 weeks, faricimab 6.0 mg T&E (previously referred to as personalized treatment interval), or aflibercept 2.0 mg every 8 weeks. The T&E up to every-16-week dosing regimen was based on central subfield thickness (CST) and BCVA change. MAIN OUTCOME MEASURES: Included changes from baseline in BCVA and CST, number of injections, durability, absence of fluid, and safety through week 100. RESULTS: In YOSEMITE and RHINE (n = 940 and 951, respectively), noninferior year 1 visual acuity gains were maintained through year 2; mean BCVA change from baseline at 2 years (weeks 92, 96, and 100 average) with faricimab every 8 weeks (YOSEMITE and RHINE, +10.7 letters and +10.9 letters, respectively) or T&E (+10.7 letters and +10.1 letters, respectively) were comparable with aflibercept every 8 weeks (+11.4 letters and +9.4 letters, respectively). The median number of study drug injections was lower with faricimab T&E (YOSEMITE and RHINE, 10 and 11 injections, respectively) versus faricimab every 8 weeks (15 injections) and aflibercept every 8 weeks (14 injections) across both trials during the entire study. In the faricimab T&E arms, durability was improved further during year 2, with > 60% of patients receiving every-16-week dosing and approximately 80% receiving every-12-week or longer dosing at week 96. Almost 80% of patients who achieved every-16-week dosing at week 52 maintained every-16-week dosing without an interval reduction through week 96. Mean CST reductions were greater (YOSEMITE/RHINE weeks 92/96/100 average: faricimab every 8 weeks -216.0/-202.6 µm, faricimab T&E -204.5/-197.1 µm, aflibercept every 8 weeks -196.3/-185.6 µm), and more patients achieved absence of DME (CST < 325 μm; YOSEMITE/RHINE weeks 92-100: faricimab every 8 weeks 87%-92%/88%-93%, faricimab T&E 78%-86%/85%-88%, aflibercept every 8 weeks 77%-81%/80%-84%) and absence of intraretinal fluid (YOSEMITE/RHINE weeks 92-100: faricimab every 8 weeks 59%-63%/56%-62%, faricimab T&E 43%-48%/45%-52%, aflibercept every 8 weeks 33%-38%/39%-45%) with faricimab every 8 weeks or T&E versus aflibercept every 8 weeks through year 2. Overall, faricimab was well tolerated, with a safety profile comparable with that of aflibercept. CONCLUSIONS: Clinically meaningful visual acuity gains from baseline, anatomic improvements, and extended durability with intravitreal faricimab up to every 16 weeks were maintained through year 2. Faricimab given as a personalized T&E-based dosing regimen supports the role of dual angiopoietin-2 and VEGF-A inhibition to promote vascular stability and to provide durable efficacy for patients with DME. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699
Fiedler, U., Reiss, Y., Scharpfenecker, M., Grunow, V., Koidl, S., Thurston, G., Gale, N. W., Witzenrath, M., Rosseau, S., Suttorp, N., et al. (2006) · Nature Medicine · doi:10.1038/nm1351 · Cited by 933
Heier, J. S., Khanani, A. M., Quezada Ruiz, C., Basu, K., Ferrone, P. J., Brittain, C., Figueroa, M. S., Lin, H., Holz, F. G., Patel, V., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00010-1 · Cited by 785
Self-citationTherapeutic targeting of the angiopoietin–TIE pathway
Saharinen, P., Eklund, L., & Alitalo, K. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.278 · Cited by 620
Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling
Felcht, M., Luck, R., Schering, A., Seidel, P., Srivastava, K., Hu, J., Bartol, A., Kienast, Y., Vettel, C., Loos, E. K., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58832 · Cited by 479
Endothelial destabilization by angiopoietin-2 via integrin β1 activation
Hakanpaa, L., Sipila, T., Leppanen, V.-M., Gautam, P., Nurmi, H., Jacquemet, G., Eklund, L., Ivaska, J., Alitalo, K., & Saharinen, P. (2015) · Nature Communications · doi:10.1038/ncomms6962 · Cited by 287
Khanani, A. M., Patel, S. S., Ferrone, P. J., Osborne, A., Sahni, J., Grzeschik, S., Basu, K., Ehrlich, J. S., Haskova, Z., & Dugel, P. U. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.2699 · Cited by 183
Self-citationAngiopoietin-2 Is Critical for Cytokine-Induced Vascular Leakage
Benest, A. V., Kruse, K., Savant, S., Thomas, M., Laib, A. M., Loos, E. K., Fiedler, U., & Augustin, H. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070459 · Cited by 178
Sahni, J., Dugel, P. U., Patel, S. S., Chittum, M. E., Berger, B., del Valle Rubido, M., Sadikhov, S., Szczesny, P., Schwab, D., Nogoceke, E., et al. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.2685 · Cited by 129
Self-citation
Metadata
- Authors
- Wong, T. Y., Haskova, Z., Asik, K., Baumal, C. R., Csaky, K. G., Eter, N., Ives, J. A., Jaffe, G. J., Korobelnik, J.-F., Lin, H., Murata, T., Ruamviboonsuk, P., Schlottmann, P. G., Seres, A. I., Silverman, D., Sun, X., Tang, Y., Wells, J. A., Yoon, Y. H., Wykoff, C. C., Aaberg, T., Abbey, A., Abdulaeva, E., Abengoechea, S., Abraham, P., Ach, T., Adams, S., Adan Civera, A., Adrean, S., Agostini, H., Alam, S., Alezzandrini, A., Alfaro, V., Aliseda, D., Almony, A., Amat, P., Amini, P., Antoszyk, A., Arias, L., Asaria, R., Avila, M., Awh, C. C., Bafalluy, J., Baker, C., Bandello, F., Barakat, M., Barraza, K., Bator, G., Baumal, C., Belfort, R., Bergstrom, C., Bertolucci, G., Bochow, T., Bolz, M., Borcz, E., Bordon, A., Boyer, D., Bratko, G., Brent, M., Brown, J., Brown, D. M., Budzinskaya, M., Buffet, S., Burgess, S., Burton, B., Busquets, M., Cabrera, F., Cagini, C., Calzada, J., Campochiaro, P., Carlson, J., Castellarin, A., Cava, C., Chaikitmongkol, V., Chan, C., Chang, E., Chang, J., Chang, A., Charles, S., Chaudhry, N., Chee, C., Chen, J., Chen, F., Chen, S.-J., Cheong-Leen, R., Chiang, A., Chittum, M., Chow, D., Connolly, B., Cornut, P. L., Csaky, K., Danzig, C., Das, A., Daskalov, V., Desco, C., Dessouki, A., Dickinson, J., Do, B., Dollin, M., Dugel, P., Dusova, J., Eichenbaum, D., Eldem, B., Engstrom, R., Ernest, J., Escobar, J. J., Esposti, S., Eter, N., Falk, N., Farkas, A., Feiner, L., Feltgen, N., Fernandez, C., Fernandez Vega, A., Ferrone, P., Figueira, J., Figueroa, M., Findl, O., Fine, H., Fortun, J., Fox, G. M., Foxman, S., Framme, C., Fraser-Bell, S., Fu, A., Fukutomi, A., Fung, N., Furno Sola, F., Gallego-Pinazo, R., Garcia, R., Garcia-Layana, A., Gawecki, M., George, S., Ghanchi, F., Ghorayeb, G., Goldberg, R., Goldstein, M., Gomes, N., Ulla, F. G., Gonzalez, V., Greven, C., Gupta, S., Guzman, M., Harris, M., Hatz, K., Hau, V., Hau, V., Hayashi, K., Heier, J., Herba, E., Hershberger, V., Higgins, P., Hirakata, A., Ho, A., Holekamp, N., Honda, S., Hsu, J., Hu, A., Hurcikova, M., Ikeda, Y., Isernhagen, R., Ito, Y., Jackson, T., Jacoby, R., Jafree, A., Javey, G., Javid, C., Jhaveri, C., Johnson, M., Kacerík, M., Kaluzny, J., Kampik, D., Kang, S. W., Kapoor, K., Karabas, L., Kawasaki, T., Kerenyi, A., Khanani, A., Khurana, R., Kim, B., Kimura, K., Kishino, G., Kitano, S., Klein-Mascia, K., Kokame, G., Korobelnik, J. F., Kulikov, A., Kuriyan, A., Kwong, H., Kwun, R., Lai, T., Lai, C.-C., Laird, P., Lalonde, L., Lanzetta, P., Larsen, M., Laugesen, C., Lavinsky, D., Lebreton, O., Lee, S., Levy, J., Lipkova, B., Liu, M., Liu, J., Lohmann, C. P., London, N., Lorenz, K., Lotery, A., Lozano Rechy, D., Lujan, S., Ma, P., Maeno, T., Mahmood, S., Makkouk, F., Malik, K., Marcus, D., Margherio, A., Mastropasqua, L., Maturi, R., McCabe, F., McKibbin, M., Mehta, H., Menon, G., Mentes, J., Michalska-Malecka, K., Misheva, A., Mitamura, Y., Mitchell, P., Modi, Y., Mohamed, Q., Montero, J., Moore, J., Morales Canton, V., Morori-Katz, H., Morugova, T., Murakami, T., Muzyka-Wozniak, M., Nardi, M., Nemcansky, J., Nester-Ostrowska, K., Neto, J., Newell, C., Nicolo, M., Nielsen, J., Noda, K., Obana, A., Ogata, N., Oh, H., Oh, K., Ohr, M., Oleksy, P., Oliver, S., Olivier, S., Osher, J., Ozcalışkan, S., Ozturk, B., Papp, A., Park, K. H., Parke, D. W., Parravano, M. C., Patel, S., Patel, S., Pearce, I., Pearlman, J., Penha, F., Perente, I., Perkins, S., Pertile, G., Petkova, I., Peto, T., Pieramici, D., Pollreisz, A., Pongsachareonnont, P., Pozdeyeva, N., Priglinger, S., Qureshi, J., Raczynska, D., Rajagopalan, R., Ramirez Estudillo, J., Raskauskas, P., Rathod, R., Razavi, H., Regillo, C., Ricci, F., Rofagha, S., Romanczak, D., Romanowska-Dixon, B., Rosberger, D., Rosenblatt, I., Rosenblatt, B., Ross, A., Ruamviboonsuk, P., Ruiz Moreno, J. M., Salomão, G., Sandhu, S., Sandner, D., Sararols, L., Sawada, O., Schadlu, R., Schlottmann, P., Schuart, C., Seitz, B., Seres, A., Sermet, F., Shah, S., Shah, A., Shah, R., Sharma, S., Sheidow, T., Sheth, V., Shimouchi, A., Shimura, M., Sikorski, B., Silva, R., Singer, M., Singerman, L., Singh, R., Souied, E., Spinak, D. J., Spital, G., Steinle, N., Stern, J., Stoller, G., Stoltz, R., Stone, C., Stone, A., Suan, E., Sugimoto, M., Sugita, I., Sun, J., Sun, X., Suner, I., Szalczer, L., Szecsko, T., Tabassian, A., Tadayoni, R., Takagi, H., Takayama, K., Taleb, A., Talks, J., Tan, G., Tanabe, T., Taylor, S., Thach, A., Thompson, J., Tlucek, P., Torti, R., Tosheva Guneva, D., Toth-Molnar, E., Uchiyama, E., Vajas, A., Varma, D., Varsanyi, B., Vassileva, P., Vaz-Pereira, S., Veith, M., Vela, J. I., Viola, F., Virgili, G., Vogt, G., Vorum, H., Weber, P., Wecke, T., Wee, R., Weger, M., Weishaar, P., Wells, J. A., Wickremasinghe, S., Williams, T. R., Williams, T., Williams, G., Wolf, A., Wolfe, J., Wong, J., Wong, D., Wong, I., Wong, R., Wowra, B., Wykoff, C. C., Wylęgała, E., Yang, C.-H., Yasukawa, T., Yates, P., Yilmaz, G., Yiu, G., Yoon, Y. H., Yoreh, B., Yoshida, S., Yu, H. G., Yu, S. Y., Yurieva, T., Zacharias, L., Zaczek Zakrzewska, K., Zambrano, A., Zatorska, B., Zeolite, C., & Zheutlin, J.
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2024-06
- Volume
- 131
- Issue
- 6
- Pages
- 708-723
- ISSN
- 0161-6420 (ISSN-L)
- OpenAlex
- W4390341908
- Cited by
- 176
- References
- 9
- FWCI
- 36.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Faricimab Treat-and-Extend for Diabetic Macular Edema. https://app.cochat.ai/papers/10.1016/j.ophtha.2023.12.026
- The paper
- Wong, T. Y., Haskova, Z., Asik, K., Baumal, C. R., Csaky, K. G., Eter, N., Ives, J. A., Jaffe, G. J., Korobelnik, J.-F., Lin, H., Murata, T., Ruamviboonsuk, P., Schlottmann, P. G., Seres, A. I., Silverman, D., Sun, X., Tang, Y., Wells, J. A., Yoon, Y. H., . . . Zheutlin, J. (2024). Faricimab Treat-and-Extend for Diabetic Macular Edema. Ophthalmology. https://doi.org/10.1016/j.ophtha.2023.12.026
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.